Clearmind Medicine Inc. has received final approval from the Hadassah Medical Center in Israel for its Phase 1/2a clinical trial evaluating CMND-100 for Alcohol Use Disorder. The trial includes top institutions like Yale and Johns Hopkins University. Clearmind aims to address the global burden of AUD, which accounts for 4.7% of all deaths worldwide. The Company’s goal is to deliver a breakthrough solution for those affected by AUD and their families. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to solve health problems, including alcohol use disorder.

Read more at GlobeNewswire: Clearmind Medicine Receives Final Approval to Expand its